Search

everythinglearnresearchcommunity

for

Search:↓

CCT128930 is a promising new drug that effectively targets and inhibits a cancer-related protein, showing potential for cancer treatment.

Teprotumumab for thyroid eye disease commonly causes fatigue, brittle nails, dry eyes, hair loss, muscle spasms, and dry mouth, with rare serious events like blood clots.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

Entospletinib effectively prevents eye and skin GVHD in mice.

Alpha-tocopherol does not prevent hair loss from doxorubicin.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

VDC-1101 shows potential as a treatment for canine cutaneous T-cell lymphoma.

Etoposide makes radiation therapy more effective against tumors without major side effects.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

TPA is about 50 times more effective at promoting tumors than MZ.

A cancer patient died from a severe skin reaction after taking the drug cetuximab.

HOTTIP and miR-10b contribute to glioma therapy resistance by affecting cell behavior, suggesting they could be targets for treatment.

Further testing of paclitaxel poliglumex for this cancer treatment is not justified.

Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.

CDK4/6 inhibitors can protect hair cells from chemotherapy damage.

Some cancer treatments can cause abnormal fine hair growth.

Balancing treatment effectiveness with side effects is crucial for relapsed follicular non-Hodgkin's lymphoma, especially in older patients.

Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.

The rash resolved after stopping ponatinib.

Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.

Treatment strategies for breast cancer affect blood health, causing issues like anemia and require nutritional counseling.

Chemotherapy causes temporary hair loss in women, while Tamoxifen does not significantly affect hair, and genetics show no link between female pattern hair loss and common baldness genes.

Erlotinib can cause persistent excessive hair growth.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.

Docetaxel often causes hair loss, with limited effective treatments and no cure for permanent hair loss.

Doxycycline can effectively treat hair loss caused by EGFR inhibitors.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Alopecia from CDK 4/6 inhibitors worsens quality of life in breast cancer patients.